Related Experiment Videos
Pseudouridine excretion in patients with psoriasis.
O J Clemmensen1, M Kieffer, K E Sjølin
1Department of Pathology, Sundby Hospital, Copenhagen, Denmark.
Acta Dermato-Venereologica
|January 1, 1987
Summary
Urinary pseudouridine levels are elevated in psoriasis patients, particularly those with psoriatic arthritis. Treatment with anthralin or PUVA significantly reduces these levels, suggesting potential for monitoring disease activity.
Area of Science:
- Biochemistry
- Dermatology
- Clinical Medicine
Background:
- Psoriasis is a chronic inflammatory skin condition.
- Biomarkers for monitoring psoriasis activity are needed.
Purpose of the Study:
- To investigate urinary pseudouridine levels in psoriasis patients.
- To assess the correlation between pseudouridine excretion and disease severity.
- To evaluate the effect of psoriasis treatments on pseudouridine levels.
Main Methods:
- Measured urinary pseudouridine excretion in 17 psoriasis patients.
- Correlated excretion levels with psoriasis extent.
- Monitored pseudouridine levels during anthralin or PUVA therapy in 10 patients.
Main Results:
- Significantly increased urinary pseudouridine excretion in psoriasis patients.
- Highest pseudouridine levels observed in patients with psoriatic arthritis.
- No correlation found between psoriasis extent and pseudouridine excretion.
- Significant decrease in pseudouridine excretion during anthralin or PUVA treatment.
Conclusions:
- Urinary pseudouridine may serve as a potential biomarker for psoriasis activity.
- Pseudouridine levels decrease with effective psoriasis treatment.
- Further research is warranted to validate pseudouridine as a monitoring tool.